Results 81 to 90 of about 19,808 (220)

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

A PK/PD study on antihyperalgesia by an α2/3‐GABAA receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1‐GABAA receptors

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose GABAA receptors (GABAARs) are heteropentameric ion channels that control almost all CNS functions, including spinal nociception. Most GABAARs contain a γ2 subunit but differ in their α and β subunit composition. TPA023B is an α2/α3 subtype selective, non‐sedative, positive allosteric modulator (PAM) with antihyperalgesic
Elena Neumann, Mariana O. Popa, Karen T. Elvers, Misa Oyama, Daniel Ulrich, Marcus Hanley, Gui Jie Feng, Thomas Hathaway, William T. Ralvenius, Thomas Grampp, Dietmar Benke, John R. Atack, Hanns Ulrich Zeilhofer   +12 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

The Polish radioligand therapy (RLT) Registry: initial real-world evidence in neuroendocrine tumors

Nuclear Medicine Review
BACKGROUND: Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE has become a key treatment option for advanced gastroenteropancreatic neuroendocrine tumors (NETs). In Poland, RLT has been reimbursed since March 2023 within the national drug program B.139.
Maciej Kołodziej, Violetta Rosiek, Jan Musiałkiewicz, Aleksandra Ledwon, Anna Lewczuk-Myślicka, Karol P. Sagan, Katarzyna Jóźwik-Plebanek, Beata Kos-Kudła, Marek Ruchała, Daria Handkiewicz-Junak, Renata Świątkowska-Stodulska, Anhelli Syrenicz, Grzegorz Kamiński   +12 more
doaj   +1 more source

Survival outcomes and prognostic factors of gastric carcinoma with neuroendocrine differentiation

International Journal of Cancer, Volume 158, Issue 9, Page 2209-2218, 1 May 2026.
What's new? Although gastric carcinoma with neuroendocrine differentiation (GCNED) is associated with more aggressive features than conventional GC, its prognosis and survival remain poorly defined. To better understand survival patterns, the authors of the present study examined clinicopathological and prognostic features of GCNED patients following ...
Jinjin Li, Chenglong Wang, Yifan Shen, Zhen Huang, Jun Zhang, Siqi Rao, Youde Cao, Jiang Min   +7 more
wiley   +1 more source

The clinical significance of epidermal growth factor receptor (egf-r) in human breast cancer: A review on 5232 patients [PDF]

, 1992
Epidermal growth factor (EGF) is a 53-aminoacid polypeptide (mol wt 6.045 K) that can influence proliferation and differentiation of a wide variety of cells (1–6).
Berns, P.M.J.J. (Els), Foekens, J.A. (John), Klijn, J.G.M. (Jan), Schmitz, P.I.M.   +3 more
core   +1 more source

Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 199-206, April 2026.
ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon‐iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee   +6 more
wiley   +1 more source

Change over time in brain serotonin transporter binding in major depression: effects of therapy measured with [(123) I]-ADAM SPECT. [PDF]

, 2013
Several studies have reported low brain serotonin transporter (SERT) binding in individuals with major depression. We hypothesized that the SERT standardized uptake ratio (SUR) values using [(123) I]-ADAM single photon emission computed tomography would ...
Amsterdam, Jay D, Newberg, MD, Andrew B., Newman, Cory F, Shults, Justine, Soeller, Irene, Wintering, Nancy   +5 more
core   +1 more source

Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells

Scientific Reports
As neuroendocrine neoplasms (NEN) undergo increasing dedifferentiation, CXC chemokine receptor type 4 (CXCR4) becomes upregulated. Higher levels of CXCR4 are associated with invasive growth, metastasis formation, and poor prognosis. CXCR4 is considered a
Christof Däubler, Clara Böttcher, Laura-Sophie Landwehr, Alexander Meining, K. Michalski, F. Reiter, Rudolf A. Werner, Philipp Hartrampf, Dorothee Rogoll, Alexander Weich   +9 more
doaj   +1 more source

Research Progress of 161Tb-PSMA Radioligand Therapy for Prostate Cancer

Journal of Isotopes
Prostate specific membrane antigen (PSMA) radioligand therapy (PRLT) has become an important new therapy，especially suitable for the treatment of metastatic castration resistant prostate cancer (mCRPC) which cannot be effectively controlled by ...
Zhengguo CHEN, Xia YANG, Liming XIAO, Bosen HU, Fucen LIU, Peng ZHAO   +5 more
doaj   +1 more source